Table 1.
Patients characteristics.
| WBRT+SIB(N=42) | SRS(N=48) | Pvalue | |
|---|---|---|---|
| Median age and range | 59(32-77) | 62(42-76) | |
| Age | |||
| ≤65 | 34(80.95%) | 28(58.33%) | 0.084 |
| >65 | 8 (19.05%) | 20(41.67%) | |
| Sex | 0.773 | ||
| Male | 17(40.48%) | 18(37.50%) | |
| Female | 25(59.52%) | 30(62.50%) | |
| BMI | 0.756 | ||
| ≤23.9 | 36(85.71%) | 40(83.3%) | |
| >23.9 | 6(14.29%) | 8(16.7%) | |
| Number of BM | P<0.005 | ||
| 1 | 7 (16.67%) | 27(56.25%) | |
| >1 | 35(83.33%) | 21(43.75%) | |
| Diameter of the largest BM | 0.245 | ||
| ≤3cm | 34(80.95%) | 43(89.58%) | |
| >3cm | 8 (19.05%) | 5 (10.42%) | |
| Histological status | 0.257 | ||
| Squamous cell | 5(11.90%) | 10(20.83%) | |
| Adenocarcinoma | 37(88.10%) | 38(79.17%) | |
| Surgery before RT | 0.488 | ||
| No | 30(71.43%) | 31(64.58%) | |
| Yes | 12(28.57%) | 17(35.42%) | |
| KPS | 0.297 | ||
| <70 | 6(14.29%) | 11(22.92%) | |
| ≥70 | 36(85.71%) | 37(77.08%) | |
| Hypertension | 0.215 | ||
| No | 19(45.24%) | 28(58.33%) | |
| Yes | 23(55.76%) | 20(41.67%) | |
| Glycuresis | 0.027 | ||
| No | 29(69.04%) | 22(45.83%) | |
| Yes | 13(30.96%) | 26(54.17%) | |
| Liver metastasis | 0.563 | ||
| No | 27(64.29%) | 28(58.33%) | |
| Yes | 15(35.71%) | 20(41.67%) | |
| Lymph metastasis | 0.706 | ||
| No | 27(64.29%) | 29(60.42%) | |
| Yes | 15(35.71%) | 19(39.58%) | |
| Contralateral lung metastasis | 0.782 | ||
| No | 30(71.42%) | 33(68.75%) | |
| Yes | 12(28.58%) | 15(31.25%) | |
| Bone metastasis | 0.461 | ||
| No | 31(73.81%) | 32(66.67%) | |
| Yes | 11(26.19%) | 16(33.33%) | |
| Chemotherapy after RT | 0.753 | ||
| No | 18(42.86%) | 19(39.58%) | |
| Yes | 24(57.14%) | 29(60.42%) | |
| Target therapy after RT | 0.571 | ||
| No | 22(52.38%) | 28(58.33%) | |
| Yes | 20(47.62%) | 20(41.67%) | |
| Immunotherapy after RT | 0.722 | ||
| No | 32(76.19%) | 35(72.92%) | |
| Yes | 10(23.81%) | 13(27.08%) | |
| Anti-angiogenic drug therapy after RT | 0.673 | ||
| No | 20(52.38%) | 25(60.42%) | |
| Yes | 22(47.62%) | 23(39.58%) | |
WBRT+SIB, Whole- Brain Radiation Therapy with Simultaneous Integrated Boost; SRS, Stereotactic Radiosurgery; BM, brain metastasis; RT, Radiotherapy; BMI, Body mass index.